2013
The impact of survivorship care plans on knowledge among breast cancer survivors.
Bulloch K, Irwin M, Chagpar A, Horowitz N, Killelea B, Pusztai L, Abu-Khalaf M, DiGiovanna M, Chung G, Hofstatter E, Levy A, Sanft T. The impact of survivorship care plans on knowledge among breast cancer survivors. Journal Of Clinical Oncology 2013, 31: 124-124. DOI: 10.1200/jco.2013.31.26_suppl.124.Peer-Reviewed Original ResearchSurvivorship care plansPotential side effectsSurveillance recommendationsSide effectsPatient knowledgeCancer survivorsCare plansLong-term side effectsCancer treatmentTreatment progressMedian patient ageBreast cancer survivorsCompletion of treatmentKnowledge of treatmentElectronic medical recordsOnly significant improvementPatient ageProspective studyTreatment detailsTumor stageCancer stageMedical recordsRisk factorsMedicine recommendationsStage III
2012
Can primary tumor markers of cancer-initiating cells predict lymph node positivity in breast cancer patients?
Chagpar A, Neumeister V, Lannin D, Rimm D. Can primary tumor markers of cancer-initiating cells predict lymph node positivity in breast cancer patients? Journal Of Clinical Oncology 2012, 30: 1121-1121. DOI: 10.1200/jco.2012.30.15_suppl.1121.Peer-Reviewed Original ResearchBreast cancer patientsLN statusCancer patientsLymphovascular invasionTumor sizeTumor markersPositive LNsPoor prognosisMedian numberPrimary tumor markersMedian patient ageMedian tumor sizeLymph node positivityLN-positive patientsLymph node statusOnly factorCancer initiating cellsCancer-initiating cellsLevels of CD44Axillary surgeryLN positivityNode positivityPatient agePositive patientsClinicopathologic data
2011
P1-01-15: Do Serum Cytokines Predict Breast Cancer Behavior?
Lush E, Dedert E, Daup M, Dhabhar F, Spiegel D, Tillie J, McMasters K, Sephton S, Chagpar A. P1-01-15: Do Serum Cytokines Predict Breast Cancer Behavior? Cancer Research 2011, 71: p1-01-15-p1-01-15. DOI: 10.1158/0008-5472.sabcs11-p1-01-15.Peer-Reviewed Original ResearchSerum cytokine levelsHormone receptor statusLymph node statusCytokine levelsReceptor statusTumor sizeBreast cancer behaviorSerum cytokinesNode statusCancer behaviorIFN-gamma serum levelsMedian patient ageMedian tumor sizeSerum IFN-gammaSerum inflammatory cytokinesProgesterone receptor statusRole of inflammationFinal pathologic resultsPresence of metastasesBreast cancer patientsBreast cancer developmentVariety of cytokinesCohort of interestLymphovascular invasionPatient ageP3-05-08: Hormone Receptor Heterogeneity in Ductal Intraepithelial Neoplasia (Ductal Carcinoma In Situ) of the Breast.
Sowden M, Flynn C, Bossuyt V, Lannin D, Chagpar A. P3-05-08: Hormone Receptor Heterogeneity in Ductal Intraepithelial Neoplasia (Ductal Carcinoma In Situ) of the Breast. Cancer Research 2011, 71: p3-05-08-p3-05-08. DOI: 10.1158/0008-5472.sabcs11-p3-05-08.Peer-Reviewed Original ResearchDuctal intraepithelial neoplasiaHormone receptor statusReceptor statusNuclear gradeIntraepithelial neoplasiaSame tumorHormonal therapyDifferent nuclear gradesHospital tumor registryMedian patient ageMajority of patientsLobular intraepithelial neoplasiaDin-2DIN 1Cohort of interestDIN patientsPR positivityPatient ageER statusPR statusTumor RegistrySingle pathologistInvasive tumorsSame patientPatients
2009
Factors influencing the decision to add chemotherapy to adjuvant hormonal therapy in women with hormone receptor-positive breast cancer.
Chagpar A, Lewis J, McMasters K, Edwards M. Factors influencing the decision to add chemotherapy to adjuvant hormonal therapy in women with hormone receptor-positive breast cancer. Cancer Research 2009, 69: 4105. DOI: 10.1158/0008-5472.sabcs-4105.Peer-Reviewed Original ResearchAddition of chemotherapyHormone receptor-positive breast cancerReceptor-positive breast cancerAbsolute survival benefitAdjuvant hormonal therapyOverall survival benefitHormonal therapySurvival benefitOverall survivalAdjuvant chemotherapyClinicopathologic factorsAbsolute benefitBreast cancerHormone receptor-positive patientsReceptor-positive patientsTamoxifen Adjuvant trialMedian patient ageMedian tumor sizeMajority of patientsYears of ageCohort of interestAdjuvant trialsLymphovascular invasionPatient agePositive disease